feed,title,long_url,short_url
Investors,"Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out",https://www.investors.com/news/technology/apogee-therapeutics-stock-eczema-treatment-dupixent-offering/,
